NCT07191249View on ClinicalTrials.gov

A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

March 1, 2029

Conditions
Follicular Lymphoma
Interventions
DRUG

Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells.

In this study, Mosunetuzumab will be administered subcutaneously over 8 treatment cycles: 5 mg on Day 1 of Cycle 1, followed by 45 mg in all subsequent cycles.

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Tel-Aviv Sourasky Medical Center

OTHER_GOV